Home/Indications/Tinea Pedis

Tinea Pedis

4 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Market Leaders

Treatments by Mechanism

Top 1 mechanisms across 1 industry trials with a known mechanism of action.

See full pipeline →

Vasodilator

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

42 industry-sponsored trials across 25 sponsors

Showing 3 of 3 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bausch Health Americas, Inc.	Luliconazole Cream 1%	—	COMPLETED	2016-04-27	NCT02767271
Bausch & Lomb Incorporated	Omeprazole 40 mg	—	COMPLETED	2015-04-01	NCT02394340
Merz North America, Inc.	NAFT500 (pediatric)	—	COMPLETED	2013-11	NCT01712360

Showing 15 of 15 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Douglas Pharmaceuticals America Ltd	Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)	—	COMPLETED	2020-05-28	NCT04203342
Biolab Sanus Farmaceutica	Dapaconazole	—	COMPLETED	2019-08-27	NCT03320486
Encube Ethicals Pvt. Ltd.	Ketoconazole Cream 2%	—	COMPLETED	2019-01-24	NCT03824912
Mylan Inc.	Econazole Nitrate Cream, 1%	—	COMPLETED	2016-11-17	NCT03129321
Genzum Life Sciences	Naftifine hydrochloride 2%	—	COMPLETED	2015-11	NCT02633813
Tinea Pharmaceuticals	Product 33525	—	COMPLETED	2012-09	NCT01349998
AmDerma	Econazole Nitrate Foam 1%	—	COMPLETED	2012-04	NCT01353976
AmDerma	Econazole Nitrate Foam 1%	—	COMPLETED	2012-04	NCT01358240
Novartis	Terbinafine	—	COMPLETED	2012-02	NCT01433107
Medicis Global Service Corporation	33525	—	COMPLETED	2012-01	NCT01396785
Medicis Global Service Corporation	33525	—	COMPLETED	2012-01	NCT01396811
Merz North America, Inc.	NAFT-600 (naftin 2 % gel)	—	COMPLETED	2011-11	NCT01290341
Merz North America, Inc.	NAFT-600 ( naftin 2 % gel )	—	COMPLETED	2011-11	NCT01289015
Merz North America, Inc.	NAFT-500	—	COMPLETED	2009-08	NCT00750139
Biolab Sanus Farmaceutica	Dapaconazole	—	WITHDRAWN	2016-12	NCT02606383

Showing 15 of 15 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Propedix, Inc.	1% Tolnaftate Stick Formula A	—	RECRUITING	2026-02	NCT07245667
Therapeutics, Inc.	UHE-103A1 cream	—	COMPLETED	2019-10-21	NCT03897257
DermBiont, Inc.	Janthinobacterium lividum	—	COMPLETED	2019-04-30	NCT04152226
South End Skin Care	Experimental Drug SESC 01	—	COMPLETED	2017-08-02	NCT03135912
Novan, Inc.	SB208 2%	—	COMPLETED	2017-01	NCT02860052
Nitric Solutions Inc.	Nitric Oxide	Vasodilator [EPC]	COMPLETED	2016-11-14	NCT02871011
Viamet	VT-1161	—	COMPLETED	2014-12	NCT01891305
AmDerma	Econazole Nitrate	—	COMPLETED	2012-04	NCT01696799
Almirall, S.A.	LAS41003	—	COMPLETED	2010-06	NCT01096472
Bayer	Bifonazole spray once daily	—	COMPLETED	2010-05	NCT01013909
Nitric BioTherapeutics, Inc	1% gaseous Nitric Oxide blended in Oxygen	—	COMPLETED	2010-01	NCT00893880
Tinea Pharmaceuticals	Luliconazole Cream 1% - 2 wks	—	COMPLETED	2009-09	NCT00869336
AmDerma	Econazole Nitrate Cream 1%	—	COMPLETED	2008-09	NCT00768599
DermBiont, Inc.	Cohort 1 J. Lividum	—	TERMINATED	2020-06-30	NCT04315051
Sol-Gel Technologies, Ltd.	S2G6T-1	—	TERMINATED	2017-10	NCT02842021

Showing 9 of 9 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Therapeutics, Inc.	UHE-103 Cream	—	COMPLETED	2023-11-14	NCT05363449
Sun Pharmaceutical Industries, Inc.	Naftifine Hydrochloride Gel 2%	—	COMPLETED	2018-05-15	NCT02335255
Sun Pharmaceutical Industries, Inc.	Naftifine Hydrochloride Cream 2%	—	COMPLETED	2014-02	NCT02132260
Sun Pharmaceutical Industries, Inc.	Naftifine HCl Cream 1%	—	COMPLETED	2013-03	NCT01580891
Sun Pharmaceutical Industries, Inc.	Butenafine Hydrochloride Cream, 1%	—	COMPLETED	2012-08	NCT01580878
Sun Pharmaceutical Industries, Inc.	Oxiconazole Nitrate Cream 1%	—	COMPLETED	2012-08	NCT01519752
Pfizer	AN2718	—	COMPLETED	2008-11	NCT00781664
Sun Pharmaceutical Industries, Inc.	Butenafine cream 1% manufactured by Taro	—	COMPLETED	2008-10	NCT00835510
Sun Pharmaceutical Industries, Inc.	Butenafine Hydrochloride 1%	—	TERMINATED	2011-03	NCT01119742

Novel Drugs by Company (New molecular entities)

JOURNEY 1 drug

SCIARRA LABS 1 drug

LACER PHARMA 1 drug

SERTACONAZOLE NITRATE

BAUSCH 1 drug

Reformulations (6 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.